Cannabis and PTSD
What the evidence actually says about using cannabis to treat post-traumatic stress disorder, separating real findings from hype.
Lots of people with PTSD say cannabis helps them sleep and feel less on edge. The lived experience is real. The clinical evidence is much thinner than activists and dispensaries imply: only a handful of randomized trials exist, and the largest one found smoked cannabis no better than placebo for overall PTSD symptoms. Cannabis is not a proven PTSD treatment. It may help specific symptoms (sleep, nightmares) for some people, but daily use carries real risks including worsening PTSD over time. Talk to a clinician.
Not medical advice
This article is not medical advice. It summarizes published evidence as of 2024. PTSD is a serious psychiatric condition. If you are struggling, talk to a licensed clinician. If you are in crisis, contact emergency services or, in the US, dial or text 988. Do not start, stop, or change any treatment based on a Weedpedia article.
Plain-language summary
PTSD is a psychiatric disorder that can develop after exposure to trauma. Core symptoms include intrusive memories, avoidance, negative mood changes, and hyperarousal (jumpiness, poor sleep, irritability) [1].
Many people with PTSD use cannabis. In US states with medical cannabis programs, PTSD is among the most common qualifying conditions, and survey data show veterans with PTSD use cannabis at higher rates than the general population [2][3]. They typically report it helps with sleep, anxiety, and nightmares.
The problem: self-report and randomized clinical trial (RCT) data don't fully agree. The best-controlled trial to date found no significant benefit of smoked cannabis over placebo for PTSD symptoms [4]. Smaller studies of the synthetic THC drug nabilone showed reduced nightmares [5]. Observational studies are mixed — some suggest short-term symptom improvement, others suggest worse long-term outcomes including increased PTSD severity and substance use problems [6][7].
Bottom line: cannabis is not a proven treatment for PTSD. It is a symptom-management tool that some patients find useful and others find harmful.
What probably works (strong evidence)
Honestly: nothing about cannabis for PTSD meets a 'strong evidence' bar yet. No data
There is no cannabis-based medicine with regulatory approval for PTSD anywhere in the world. The clinical trial literature is small, short, and inconsistent. Anyone telling you cannabis is a proven PTSD treatment is overselling the data.
What does have strong evidence for PTSD are non-cannabis treatments — see the comparison section below.
What might work (weak evidence)
Nabilone for trauma-related nightmares. Nabilone is a synthetic THC analog. A small randomized crossover trial in Canadian military personnel (N=10) showed reduced nightmare frequency and severity versus placebo [5]. Weak / limited Open-label studies in incarcerated populations reported similar effects. This is the closest thing to a positive cannabinoid finding in PTSD, but the studies are small.
Short-term sleep improvement. THC reduces time to sleep onset and total REM sleep in healthy users and some PTSD patients. Because PTSD nightmares occur in REM, REM suppression is a plausible mechanism for the nightmare effect [8]. Weak / limited However, tolerance develops, REM rebounds when use stops, and chronic use disrupts sleep architecture.
Acute anxiety reduction. Low-dose THC and CBD have shown acute anxiolytic effects in laboratory anxiety paradigms in non-PTSD populations [9]. Whether this translates to clinically meaningful PTSD benefit is unclear. Weak / limited
CBD for PTSD. An open-label case series of 11 patients reported reduced PTSD symptoms with adjunctive CBD over 8 weeks [10]. No placebo control, very small sample. Weak / limited
What doesn't work, or has weak/negative evidence
Smoked whole-plant cannabis for overall PTSD symptoms. The most rigorous trial to date, MAPS-sponsored and conducted at the Scottsdale Research Institute, randomized 80 veterans with chronic PTSD to high-THC, high-CBD, balanced THC/CBD, or placebo cannabis. All groups improved. There were no significant differences between active cannabis and placebo on the primary PTSD outcome measure [4]. Strong evidence
'Indica strains are better for PTSD.' The indica/sativa distinction does not reliably predict effects and isn't a meaningful chemical category [11]. Disputed Cannabinoid and terpene content vary widely within both labels. See Indica vs Sativa.
High-THC daily use as a long-term strategy. Longitudinal data from VA cohorts suggest veterans with PTSD who initiate or continue cannabis use show worse PTSD symptom trajectories and higher rates of cannabis use disorder compared to those who stop or never use [6][7]. Weak / limited These are observational, so causation is unclear — sicker patients may self-select into heavier use — but the data do not support cannabis as a long-term symptom solution.
What we don't know
- Whether specific cannabinoid ratios (e.g. balanced THC:CBD vs. THC-dominant) differ meaningfully for PTSD outcomes.
- Whether CBD alone has any clinically useful effect on PTSD. Trials are ongoing.
- Whether cannabis interferes with evidence-based trauma psychotherapies like prolonged exposure or CPT. There is theoretical concern that THC could blunt the extinction learning these therapies depend on, but data are limited [12]. Weak / limited
- Optimal dose, route, frequency, and duration for any symptom indication.
- Whether MDMA-assisted therapy (a different psychedelic-adjacent treatment with strong Phase 3 data, though FDA-rejected in 2024) is meaningfully different from cannabinoid approaches.
- Long-term cognitive and psychiatric effects of daily medical cannabis use in trauma-exposed populations.
Comparison with standard treatments
For PTSD, the treatments with the strongest evidence are not pharmacological at all — they are trauma-focused psychotherapies [1][13]: Strong evidence
- Prolonged Exposure (PE) — large effect sizes across multiple RCTs.
- Cognitive Processing Therapy (CPT) — comparable efficacy.
- EMDR — effective, though mechanism debated.
For medications, the FDA has approved two SSRIs (sertraline and paroxetine) for PTSD. Effect sizes are modest but supported by multiple RCTs [13]. Strong evidence Prazosin has weak-to-moderate evidence for trauma nightmares [14]. Weak / limited
Cannabis sits well below all of these in evidence quality. A reasonable clinical framing: trauma-focused therapy is first line; SSRIs are second line; cannabis is, at best, an adjunct for specific symptoms (sleep, nightmares) in patients who have tried or declined first-line options — and even then, with eyes open about risks.
Risks
Real risks to weigh against possible symptom relief:
- Cannabis use disorder (CUD). People with PTSD develop CUD at higher rates than the general population [3]. Strong evidence PTSD is itself a risk factor for problematic use.
- Worse PTSD over time in observational cohorts of continued users [6]. Weak / limited
- Psychosis risk, especially with high-THC products in young or genetically vulnerable users [15]. Strong evidence
- Disrupted sleep architecture with chronic use, and rebound insomnia / nightmare resurgence on cessation [8]. Weak / limited
- Interference with extinction learning that trauma therapies rely on — theoretical but biologically plausible [12]. Weak / limited
- Cognitive effects: working memory, attention, particularly with daily heavy use.
- Drug interactions with SSRIs, benzodiazepines, and other psychiatric medications.
If you use cannabis for PTSD, lower-risk practices include: avoiding daily heavy THC use, not using as your only treatment, being honest with your clinician, and watching for escalating use or worsening symptoms.
Sources
- Book American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.
- Peer-reviewed Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. American Journal of Drug and Alcohol Abuse. 2014;40(1):23-30.
- Peer-reviewed Kevorkian S, Bonn-Miller MO, Belendiuk K, Carney DM, Roberson-Nay R, Berenz EC. Associations among trauma, posttraumatic stress disorder, cannabis use, and cannabis use disorder in a nationally representative epidemiologic sample. Psychology of Addictive Behaviors. 2015;29(3):633-638.
- Peer-reviewed Bonn-Miller MO, Sisley S, Riggs P, et al. The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial. PLOS ONE. 2021;16(3):e0246990.
- Peer-reviewed Jetly R, Heber A, Fraser G, Boisvert D. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology. 2015;51:585-588.
- Peer-reviewed Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. Journal of Clinical Psychiatry. 2015;76(9):1174-1180.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports. 2017;19(4):23.
- Peer-reviewed Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226.
- Peer-reviewed Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the treatment of post-traumatic stress disorder: a case series. Journal of Alternative and Complementary Medicine. 2019;25(4):392-397.
- Peer-reviewed Piomelli D, Russo EB. The Cannabis sativa versus Cannabis indica debate: an interview with Ethan Russo, MD. Cannabis and Cannabinoid Research. 2016;1(1):44-46.
- Peer-reviewed Rabinak CA, Angstadt M, Lyons M, et al. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans. Neurobiology of Learning and Memory. 2014;113:125-134.
- Government US Department of Veterans Affairs / Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. 2023. ↗
- Peer-reviewed Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine. 2018;378(6):507-517.
- Peer-reviewed Di Forti M, Quattrone D, Freeman TP, et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry. 2019;6(5):427-436.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...